Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

• Chung-Feng Huang,
• Manar Hijaze Awad,
• Meital Gal-Tanamy,
• Ming-Lung Yu

Affiliations

Chung-Feng Huang

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan

Manar Hijaze Awad

Molecular Virology Lab, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel

Meital Gal-Tanamy

Molecular Virology Lab, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel

Ming-Lung Yu

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan